美国 · SEC FORM 4
Akebia Therapeutics, Inc.
AKBA · Nasdaq · CIK 0001517022 · Healthcare · Drug Manufacturers—Specialty & Generic
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
8 同一窗口内观察到的 Form 4 交易行
1 sales · 7 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
Showing the six most active owners; 2 additional owner(s) remain in Form 4 申报证据.
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后,这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2026-03-04 · Butler John P..
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
市场背景补充近期价格表现与风险信息,不影响内部人信号。
价格表现
- 1M
- -12.7%
- 3M
- -34.2%
- 6M
- -38.0%
- 12M
- —
波动率与流动性
- 波动率
- 78.2%
- Beta
- —
- 平均每日成交额
- —
估值
- 市值
- —
- P/E
- —
基本面
- 利润率
- -2.2%
- ROE
- -16.3%
- 细分行业
- Drug Manufacturers—Specialty & Generic
市场数据
价格数据截至:2026-10-02 · 价格来源:OpenBB/yfinance · 来自 SEC 申报文件:利润率, ROE · 财年截止日:2025-12-31 · Status: PASS
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 22,481,147
- 上期报告
- 20,504,915
- 日均成交量
- 6,412,381
- 回补天数
- 3.5
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-03-04 | Butler John P. | 买入 (P) | Common Stock | 69,270 | USD 1.25 | USD 86,588 | SEC 申报 ↗ |
Form 4 申报证据
31 transaction lines in the latest 365-day window; 219 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-06 | Butler John P. | 期权行权/转换 (M) | Common Stock | 350,000 | USD 0.63 | USD 220,500 | SEC 申报 ↗ |
| 2026-06-29 | Ostrowski Erik | 卖出 (S) | Common Stock | 56,019 | USD 1.11 | USD 62,181 | SEC 申报 ↗ |
| 2026-06-17 | ZUMWALT LEANNE M | 奖励/授予 (A) | Common Stock | 35,700 | USD 0.00 | USD 0 | SEC 申报 ↗ |
展开近期 Form 4 证据 (22 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-06 | Butler John P. | 期权行权/转换 (M) | Common Stock | 350,000 | USD 0.63 | USD 220,500 | SEC 申报 ↗ |
| 2026-06-29 | Ostrowski Erik | 卖出 (S) | Common Stock | 56,019 | USD 1.11 | USD 62,181 | SEC 申报 ↗ |
| 2026-06-17 | ZUMWALT LEANNE M | 奖励/授予 (A) | Common Stock | 35,700 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-17 | Wolf Myles | 奖励/授予 (A) | Common Stock | 35,700 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-17 | Smith Cynthia | 奖励/授予 (A) | Common Stock | 35,700 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-17 | ROGERS MICHAEL W | 奖励/授予 (A) | Common Stock | 35,700 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-17 | FRIESON RON | 奖励/授予 (A) | Common Stock | 35,700 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-06-17 | ADAMS ADRIAN | 奖励/授予 (A) | Common Stock | 35,700 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-03-04 | Butler John P. | 买入 (P) | Common Stock | 69,270 | USD 1.25 | USD 86,588 | SEC 申报 ↗ |
| 2026-02-02 | Rucci Carolyn M. | 卖出 (S) | Common Stock | 69,772 | USD 1.39 | USD 96,983 | SEC 申报 ↗ |
| 2026-02-02 | Ostrowski Erik | 卖出 (S) | Common Stock | 34,951 | USD 1.39 | USD 48,582 | SEC 申报 ↗ |
| 2026-02-02 | Malabre Richard C | 卖出 (S) | Common Stock | 49,524 | USD 1.39 | USD 68,838 | SEC 申报 ↗ |
| 2026-02-02 | Grund Nicholas | 卖出 (S) | Common Stock | 84,829 | USD 1.39 | USD 117,912 | SEC 申报 ↗ |
| 2026-02-02 | Butler John P. | 卖出 (S) | Common Stock | 341,305 | USD 1.39 | USD 474,414 | SEC 申报 ↗ |
| 2026-02-02 | Butler John P. | 奖励/授予 (A) | Common Stock | 175,250 | USD 1.41 | USD 247,102 | SEC 申报 ↗ |
| 2026-02-02 | Burke Steven Keith | 卖出 (S) | Common Stock | 67,658 | USD 1.39 | USD 94,045 | SEC 申报 ↗ |
| 2026-01-30 | Rucci Carolyn M. | 奖励/授予 (A) | Common Stock | 190,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-30 | Ostrowski Erik | 奖励/授予 (A) | Common Stock | 204,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-30 | Malabre Richard C | 奖励/授予 (A) | Common Stock | 79,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-30 | Grund Nicholas | 奖励/授予 (A) | Common Stock | 204,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-30 | Butler John P. | 奖励/授予 (A) | Common Stock | 743,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
| 2026-01-30 | Burke Steven Keith | 奖励/授予 (A) | Common Stock | 204,000 | USD 0.00 | USD 0 | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | AKBA |
| CIK | 0001517022 |
| 行业 | Healthcare |
| 细分行业 | Drug Manufacturers—Specialty & Generic Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 219 transaction lines from 2020-02-28 to 2026-08-06 1 P purchase lines · 110 S sale lines · 108 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.